Franco Junior, Jose Gonçalves [UNESP]Oliveira, Joao Batista A [UNESP]Petersen, Claudia G [UNESP]Mauri, Ana L. [UNESP]Baruffi, Ricardo LR [UNESP]Cavagna, Mario [UNESP]2014-05-272014-05-272011-09-01Jornal Brasileiro de Reproducao Assistida, v. 15, n. 5, p. 39-43, 2011.1517-56931518-0557http://hdl.handle.net/11449/72626Infertility represents one of the main long-term consequences of combination chemotherapy used for the treatment of breast cancer. Approximately 60%-65% of breast cancers express the nuclear hormone receptor in premenopausal women. Adjuvant endocrine therapy is an integral component of care for patients with hormone receptor-positive (HR+) tumours. The GnRH agonist (GnRHa) alone or in combination with tamoxifen produces results at least similar to those obtained with the different chemotherapy protocols in patients with HR+ tumors with respect to recurrence-free survival and overall survival, Presentation of the hypothesis: It is time to indicate adjuvant therapy with GnRHa associated with tamoxifen for patients with breast cancer (HR+ tumours) if they want to preserve their reproductive function. Testing the hypothesis: Assessment of ovarian reserve tests: follicle stimulating hormone (FSH), anti-Mullerian hormone (AMH), inhibin B, antral follicle count (AFC) and ovarian volume 6 months, and 1 year after the end of therapy with GnRHa/tamoxifen. The recurrence-free survival and overall survival should be analysed. Implications of the hypothesis: The major implication will be to avoid adjuvant chemotherapy for patients with breast cancer (HR+ tumours) that request fertility preservation. It is expected that ovarian function should not be altered in almost all cases. © Todos os direitos reservados a SBRA - Sociedade Brasileira de Reprodução Assistida.39-43engAdjuvant therapyBreast cancerChemotherapyFertility preservationGnRHaHormone receptor-positiveTamoxifenCyclophosphamideFluorouracilFollitropinGonadorelin agonistHormone receptorInhibin BMethotrexateMuellerian inhibiting factorTamoxifenAdjuvant therapyAmenorrheaBreast cancerDisease associationDisease free survivalFertilityHumanHypergonadotropismOvarian reserveOvary functionOvary insufficiencyOverall survivalReproductionArtigoAcesso restrito2-s2.0-80052392800